Neil Bodick, chief scientific officer of Flexion Therapeutics (NASDAQ: FLXN), will retire on Jan. 3. After co-founding the company in 2007, Bodick served as its chief medical officer. He became chief scientific officer in 2017 following FDA approval of the company’s extended-release formulation of triamcinolone acetonide (Zilretta), a treatment for knee pain. After retiring, Flexion says Bodick will continue in a consulting role to help in the transition of his responsibilities. Burlington, MA-based Flexion develops therapies for musculoskeletal conditions.